Royce & Associates’s BioCryst Pharmaceuticals BCRX Stock Holding History

Royce & Associates’s Portfolio BCRX Stock Details BCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-84,855	Closed	-$685K	–	1145
2018 Q4	$685K	Sell	84,855 -59,145	-41%	-$460K	0.01%	899
2018 Q3	$1.1M	Hold	144,000	–	–	0.01%	908
2018 Q2	$825K	Hold	144,000	–	–	0.01%	975
2018 Q1	$687K	Hold	144,000	–	–	﹤0.01%	1020
2017 Q4	$707K	Hold	144,000	–	–	﹤0.01%	1020
2017 Q3	$755K	Hold	144,000	–	–	0.01%	998
2017 Q2	$801K	Hold	144,000	–	–	0.01%	1002
2017 Q1	$1.21M	Hold	144,000	–	–	0.01%	955
2016 Q4	$912K	Sell	144,000 -16,000	-10%	-$83.3K	0.01%	955
2016 Q3	$706K	Hold	160,000	–	–	﹤0.01%	966
2016 Q2	$454K	Hold	160,000	–	–	﹤0.01%	995
2016 Q1	$453K	Buy	+160,000	New	+$709K	﹤0.01%	993

Other funds holding BCRX

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

VMI

VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return

Royce & Associates's BCRX Position: Q1 2019 in Review

Royce & Associates sold out of BioCryst Pharmaceuticals (BCRX) in Q1 2019, closing a stake of 84,855 shares — an estimated $685K sold.

Royce & Associates first reported a position in BCRX in Q1 2016 and held it in 12 quarters. The position peaked at $1.21M in Q1 2017. 133 funds tracked by Wall St. Rank hold BCRX as of Q1 2019.

Royce & Associates reported no remaining BioCryst Pharmaceuticals position as of Q1 2019 after selling out during the quarter.
Royce & Associates sold 84,855 BioCryst Pharmaceuticals shares in Q1 2019, an estimated $685K.
Royce & Associates first reported a position in BioCryst Pharmaceuticals in Q1 2016 and held it in 12 quarters.
Royce & Associates's BioCryst Pharmaceuticals position peaked at $1.21M in Q1 2017.
133 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q1 2019.

Based on Royce & Associates's 13F filing for Q1 2019, filed 9 May 2019.